Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on March 6, 2018. The filing addresses a regulatory event concerning the company's listing status on the Nasdaq Capital Market. Note: The request metadata references "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stock price compliance requirements.
Material Changes
The primary material event is the notification from the Nasdaq Capital Market granting the company an additional 180 calendar days to regain compliance with the minimum bid price requirement. The new deadline to demonstrate compliance is September 4, 2018.
Guidance, Outlook, and Risks
- Compliance Requirement: To maintain its listing, the company's common stock must close at or above $1.00 per share for a minimum of ten consecutive trading days prior to September 4, 2018.
- Risk: Failure to meet the $1.00 bid price threshold within the extended period could result in delisting from the Nasdaq Capital Market.
- Management Commentary: The filing contains no forward-looking financial guidance or management commentary beyond the notification of the compliance extension.
Investor Verification Checklist
- Verify the current trading price of Trovagene, Inc. common stock relative to the $1.00 threshold.
- Monitor the stock's closing prices to track progress toward the required ten consecutive trading days above $1.00.
- Confirm the company's status on the Nasdaq Capital Market leading up to the September 4, 2018 deadline.
- Review subsequent filings for any updates on the company's financial health or capital raising activities intended to support the stock price.